SAN DIEGO, Jan. 06, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the company will present at the Biotech Showcase™ at 4:00 PM Pacific Time (7:00 PM Eastern Time) on Tuesday, January 10, 2017. The presentation will take place in Room 3 (Ballroom Level) at the Hilton San Francisco Union Square.
Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments, including progress on its clinical pipeline.
A live audio webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com. A replay of the presentation will be available for 90 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Biotech Showcase
The Biotech Showcase 2017 Conference (http://www.ebdgroup.com/bts/index.php) is one of the most significant healthcare investor conferences of the year. It is designed to provide private and public biotechnology and life sciences companies the opportunity to present to, and meet with, public and private investors, and pharmaceutical executives. This is the 9th year for the Biotech Showcase. More than 2100 investors and biopharmaceutical executives from around the world are expected to attend.
About Cytori
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties are described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports.
There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.
Cytori Therapeutics, Inc. Tiago Girao, +1 (858) 458.0900 [email protected]


Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
OpenAI Explores Massive Funding Round at $750 Billion Valuation
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 



